Search Results - "Orts, Beatriz"
-
1
Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease
Published in Frontiers in pharmacology (03-01-2022)“…Up to 40% of patients with Crohn's disease do not respond to treatment with anti-TNF or lose response after the initial benefit. Low drug concentrations have…”
Get full text
Journal Article -
2
Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy
Published in Inflammatory bowel diseases (05-01-2022)“…Abstract Background A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety…”
Get full text
Journal Article -
3
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Published in Inflammatory bowel diseases (05-01-2022)Get full text
Journal Article -
4
Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration
Published in Revista española de enfermedades digestivas (01-06-2022)“…Carboxymaltose iron (Ferinject®) is a formulation for intravenous (iv) administration, used for the treatment of iron deficiency anemia and/or iron deficiency…”
Get full text
Journal Article -
5
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn’s Disease: Real World Evidence From the ENEIDA Registry
Published in Journal of Crohn's and colitis (27-01-2023)“…Abstract Background and Aims Clinical trials and real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy and safety profile…”
Get full text
Journal Article -
6